Q. Please introduce Lonza as a CDMO

A. Lonza is one of the world’s largest healthcare manufacturing organizations which provides contract development and manufacturing services for pharma and biotech companies across five continents. We manage projects from pre-clinical development stage through to commercialization across mammalian and microbial produced biologics, , bioconjugates, mRNA, small molecules and cell and gene therapies. Our extensive service portfolio covers both drug substance and drug product.

In 2023, the company worked on more than 195 projects* for commercial drugs and on more than 880 projects** for pre-clinical and clinical trials. Thanks to its proven track record in the industry, Lonza has built a reputation as a trusted partner throughout the drug development and manufacturing journey across a range of modalities.

* As of December 2023, including mammalian, microbial, bioconjugates, drug product services and cell and gene therapy products (personalized medicines are included in pre-clinical and clinical molecules only, early development services are included for pre-clinical molecules only)

** As of December 2023, including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering

Q. Lonza will give a presentation on DAY1 about ADC, which is currently a hot topic in pharma industry in Korea. What is the key message that audience pay attention to?

A. Leveraging nearly two decades of experience in the development and manufacturing of these complex treatments, we produce many commercially available ADCs today. We develop and produce all components of bioconjugates, supporting customers in accelerating timelines and reducing complexity on the journey to commercialization. At the Insight Session during BIOPLUS-Interphex Korea 2024, our expert will talk about Lonza's approach to early ADC de-risking and development to help design and de-risk molecules, streamlining the path to GMP manufacturing and clinical trials.

Q.  The pharma industry in Korea is predominantly composed by small biotech companies with molecules in pre-clinical stages, from late discovery to IND. How is Lonza supporting such companies?

A. We continuously work with small biotech companies on their unique path to IND by offering personalized development and manufacturing programs to meet their timelines, molecule needs and investors’ requirements. Drug development has become increasingly competitive and leaves little room for error or delay. Selecting and optimizing the right lead candidate is critical and helps to maximize the chances of a successful First-in-Human campaign. For decades, Lonza’s CMC and Early Development experts have been supporting biotech and pharma customers in not only assessing, de-risking, and optimizing biotherapeutic drug candidates, but also in taking them all the way to the clinic.

Q. Please introduce Lonza's main vision and goals in the future.

A. Our vision is to bring any therapy to life. Our vision reflects our goal to meet any customer need through our expertise and manufacturing excellence. More widely, our vision expresses our ambition to improve patients’ lives by supporting our customers on the path to commercialization.

We support our customers with integrated and cross-divisional capabilities. We have one of the most complete offerings in the CDMO industry, across technologies and scale, helping us bring new drugs to the market quickly and securely. Our breadth of offerings is strengthened by our growth strategy, which focuses on building capability and capacity in areas of high market growth and demand. We also continue to invest in innovation to support the development and manufacturing of emerging modalities.